Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques

DOI Web Site Web Site 被引用文献2件
  • Ling Xu
    Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
  • Amarendra Pegu
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • Ercole Rao
    Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
  • Nicole Doria-Rose
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • Jochen Beninga
    Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
  • Krisha McKee
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • Dana M. Lord
    Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
  • Ronnie R. Wei
    Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
  • Gejing Deng
    Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
  • Mark Louder
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • Stephen D. Schmidt
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • Zachary Mankoff
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • Lan Wu
    Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
  • Mangaiarkarasi Asokan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • Christian Beil
    Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
  • Christian Lange
    Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
  • Wulf Dirk Leuschner
    Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
  • Jochen Kruip
    Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
  • Rebecca Sendak
    Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
  • Young Do Kwon
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • Tongqing Zhou
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • Xuejun Chen
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • Robert T. Bailer
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • Keyun Wang
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • Misook Choe
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • Lawrence J. Tartaglia
    Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Dan H. Barouch
    Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Sijy O’Dell
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • John-Paul Todd
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • Dennis R. Burton
    Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Mario Roederer
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • Mark Connors
    National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • Richard A. Koup
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • Peter D. Kwong
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • Zhi-yong Yang
    Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.
  • John R. Mascola
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • Gary J. Nabel
    Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.

説明

<jats:title>A triple threat for HIV</jats:title> <jats:p> The HIV virus continually evolves tricks to evade elimination by the host. Prevention and a cure will likely rely on broadly neutralizing antibodies that can recognize and conquer multiple viral strains or subtypes. Xu <jats:italic>et al.</jats:italic> engineered a single antibody molecule to recognize three highly conserved proteins needed for HIV infection (see the Perspective by Cohen and Corey). This “trispecific” antibody uses two sites (V1V2 and MPER) to bind HIV-infected cells, while the third site (CD4bs) recruits killer T lymphocytes that can eliminate the virus. When tested against >200 different HIV strains, trispecific antibodies were highly potent and broadly neutralized ∼99% of HIV viruses. This approach could potentially simplify HIV treatment regimens and improve therapy response. </jats:p> <jats:p> <jats:italic>Science</jats:italic> , this issue p. <jats:related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" issue="6359" page="85" related-article-type="in-this-issue" vol="358" xlink:href="10.1126/science.aan8630">85</jats:related-article> ; see also p. <jats:related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" issue="6359" page="46" related-article-type="in-this-issue" vol="358" xlink:href="10.1126/science.aap8131">46</jats:related-article> </jats:p>

収録刊行物

  • Science

    Science 358 (6359), 85-90, 2017-10-06

    American Association for the Advancement of Science (AAAS)

被引用文献 (2)*注記

もっと見る

問題の指摘

ページトップへ